Fas ligand promotes tumor immune evasion of colon cancer in vivo

Cell Cycle

Volumn 5, Issue 3, 2006, Pages 246-249

  Ryan, Aideen E ^a   Shanahan, Fergus ^a,b   O'Connell, Joe ^a,b   Houston, Aileen M ^a,b,c  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b UNIVERSITY COLLEGE CORK   (Ireland)

^c University College Cork and INFANT Centre   (Ireland)

Author keywords

Anti inflammatory; Antisense inhibition; Fas ligand; Immune privilege; Tumor development

Indexed keywords

COMPLEMENTARY DNA; FAS LIGAND;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLON CANCER; COLON CARCINOGENESIS; CYTOKINE RELEASE; DOWN REGULATION; IMMUNOCOMPETENCE; IN VIVO STUDY; INFLAMMATION; LYMPHOCYTIC INFILTRATION; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROVOCATION TEST; TUMOR ESCAPE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR VOLUME; UPREGULATION;

ANIMALIA;

EID: 32244434882     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.5.3.2413     Document Type: Article

References (33)

1. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75:1169-78.
2. Nagata S, Golstein P. The Fas death factor. Science 1995; 267:1449-56.
3. Brunner T, Wasem C, Torgler R, Cima I, Jakob S, Corazza N. Fas (CD95/Apo-1) ligand regulation in T cell homeostasis, cell-mediated cytotoxicity and immune pathology. Semin Immunol 2003; 15:167-76.
4. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995; 270:1189-92.
5. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC. A role for CD95 ligand in preventing graft rejection. Nature 1995; 377:630-2.
6. Krammer PH. CD95's deadly mission in the immune system. Nature 2000; 407:789-95.
7. Houston A, Waldron-Lynch FD, Bennett MW, Roche D, O'Sullivan GC, Shanahan F, O'Connell J. Fas ligand expressed in colon cancer is not associated with increased apoptosis of tumor cells in vivo. Int J Cancer 2003; 107:209-14.
8. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996; 184:1075-82.
9. Niehans GA, Brunner T, Frizelle SP, Liston JC, Salerno CT, Knapp DJ, Green DR, Kratzke RA. Human lung carcinomas express Fas ligand. Cancer Res 1997; 57:1007-12.
10. Bennett MW, O'Connell J, O'Sullivan GC, Brady C, Roche D, Collins JK, Shanahan F. The Fas counterattack in vivo: Apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol 1998; 160:5669-75.
11. Okada K, Komuta K, Hashimoto S, Matsuzaki S, Kanematsu T, Koji T. Frequency of apoptosis of tumor-infiltrating lymphocytes induced by fas counterattack in human colorectal carcinoma and its correlation with prognosis. Clin Cancer Res 2000; 6:3560-4.
12. Houston A, Bennett MW, O'Sullivan GC, Shanahan F, O'Connell J. Fas ligand mediates immune privilege and not inflammation in human colon cancer, irrespective of TGF-beta expression. Br J Cancer 2003; 89:1345-51.
13. O'Connell J, Houston A, Bennett MW, O'Sullivan GC, Shanahan F. Immune privilege or inflammation? Insights into the Fas ligand enigma. Nat Med 2001; 7:271-4.
14. Kang SM, Schneider DB, Lin Z, Hanahan D, Dichek DA, Stock PG, Baekkeskov S. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat Med 1997; 3:738-43.
15. Seino K, Kayagaki N, Okumura K, Yagita H. Antitumor effect of locally produced CD95 ligand. Nat Med 1997; 3:165-70.
16. Ryan AE, Shanahan F, O'Connell J, Houston AM. Addressing the "Fas counterattack" controversy: Blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo. Cancer Res 2005; 65:9817-23.
17. Saloman DS, Bianco C, Ebert AD, Khan NI, De Santis M, Normanno N, Wechselberger C, Seno M, Williams K, Sanicola M, Foley S, Gullick WJ, Persico G. The EGF-CFC family: Novel epidermal growth factor-related proteins in development and cancer. Endocr Relat Cancer 2000; 7:199-226.
18. Cardi G, Heaney JA, Schned AR, Ernstoff MS. Expression of Fas(APO-1/CD95) in tumor-infiltrating and peripheral blood lymphocytes in patients with renal cell carcinoma. Cancer Res 1998; 58:2078-80.
19. Lepple-Wienhues A, Belka C, Laun T, Jekle A, Walter B, Wieland U, Welz M, Heil L, Kun J, Busch G, Weller M, Bamberg M, Gulbins E, Lang F. Stimulation of CD95 (Fas) blocks T lymphocyte calcium channels through sphingomyelinase and sphingolipids. Proc Natl Acad Sci USA 1999; 96:13795-800.
20. Stohl W, Xu D, Starling GC, Casali P, Kiener PA. Promotion of activated human B cell apoptosis and inhibition of Ig production by soluble CD95 ligand: CD95-based downregulation of Ig production need not culminate in activated B cell death. Cell Immunol 2000; 203:1-11.
21. Taylor DD, Gercel-Taylor C, Lyons KS, Stanson J, Whiteside TL. T-cell apoptosis and suppression of T-cell receptor/CD3-zeta by Fas ligand-containing membrane vesicles shed from ovarian tumors. Clin Cancer Res 2003; 9:5113-9.
22. Barnhart BC, Legembre P, Pietras E, Bubici C, Franzoso G, Peter ME. CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells. Embo J 2004; 22:22.
23. Desbarats J, Birge RB, Mimouni-Rongy M, Weinstein DE, Palerme JS, Newell MK. Fas engagement induces neurite growth through ERK activation and p35 upregulation. Nat Cell Biol 2003; 5:118-25.
24. Legembre P, Barnhart BC, Zheng L, Vijayan S, Straus SE, Puck J, Dale JK, Lenardo M, Peter ME. Induction of apoptosis and activation of NF-kappaB by CD95 require different signalling thresholds. EMBO Rep 2004; 5:1084-9.
25. Shinohara H, Yagita H, Ikawa Y, Oyaizu N. Fas drives cell cycle progression in glioma cells via extracellular signal-regulated kinase activation. Cancer Res 2000; 60:1766-72.
26. Lambert C, Landau AM, Desbarats J. Fas-beyond death: A regenerative role for Fas in the nervous system. Apoptosis 2003; 8:551-62.
27. Kim JW, Wieckowski E, Taylor DD, Reichert TE, Watkins S, Whiteside TL. Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clin Cancer Res 2005; 11:1010-20.
28. Hohlbaum AM, Moe S, Marshak-Rothstein A. Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival. J Exp Med 2000; 191:1209-20.
29. Hohlbaum AM, Gregory MS, Ju ST, Marshak-Rothstein A. Fas ligand engagement of resident peritoneal macrophages in vivo induces apoptosis and the production of neutrophil chemotactic factors. J Immunol 2001; 167:6217-24.
30. Frederick MJ, Clayman GL. Chemokines in cancer. Expert Rev Mol Med 2001; 2001:1-18.
31. Haraguchi M, Komuta K, Akashi A, Matsuzaki S, Furui J, Kanematsu T. Elevated IL-8 levels in the drainage vein of resectable Dukes' C colorectal cancer indicate high risk for developing hepatic metastasis. Oncol Rep 2002; 9:159-65.
32. Bates RC, DeLeo IIIrd MJ, Mercurio AM. The epithelial-mesenchymal transition of colon carcinoma involves expression of IL-8 and CXCR-1-mediated chemotaxis. Exp Cell Res 2004; 299:315-24.
33. Bennett MW, O'Connell J, Houston A, Kelly J, O'Sullivan GC, Collins JK, Shanahan F. Fas ligand upregulation is an early event in colonic carcinogenesis. J Clin Pathol 2001; 54:598-604.